U Fuhr

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. pmc Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
    C Breuer
    ITECRA GmbH and Co KG, Weyertal 76, 50931, Koln, Germany
    Eur J Clin Pharmacol 69:1303-10. 2013
  2. doi request reprint Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers
    Oxana Doroshyenko
    ITECRA GmbH and Co KG, Cologne, Germany
    Drug Metab Dispos 41:987-93. 2013
  3. ncbi request reprint Individual variation in factors affecting the steps between dose application and effects of antineoplastic agents
    U Fuhr
    Department of Pharmacology, University of Cologne, Germany
    Int J Clin Pharmacol Ther 43:573-4. 2005
  4. ncbi request reprint Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicity
    Uwe Fuhr
    Department of Pharmacology, University Hospital, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany
    Cancer Epidemiol Biomarkers Prev 15:266-71. 2006
  5. ncbi request reprint Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach
    U Fuhr
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
    Clin Pharmacol Ther 81:270-83. 2007
  6. doi request reprint Improvement in the handling of drug-drug interactions
    Uwe Fuhr
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Koln, Germany
    Eur J Clin Pharmacol 64:167-71. 2008
  7. ncbi request reprint The effect of silymarin on oral nifedipine pharmacokinetics
    Uwe Fuhr
    Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
    Planta Med 73:1429-35. 2007
  8. doi request reprint Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan
    K Abduljalil
    Department of Pharmacology, Clinical Pharmacology Unit, University Hospital, University of Cologne, Cologne, Germany
    Clin Pharmacol Ther 88:643-51. 2010
  9. doi request reprint Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?
    D Tomalik-Scharte
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
    Clin Pharmacol Ther 86:147-53. 2009
  10. doi request reprint Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
    J J Vehreschild
    Department I of Internal Medicine, University of Cologne, Cologne, Germany
    Eur J Clin Pharmacol 68:987-95. 2012

Collaborators

Detail Information

Publications58

  1. pmc Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
    C Breuer
    ITECRA GmbH and Co KG, Weyertal 76, 50931, Koln, Germany
    Eur J Clin Pharmacol 69:1303-10. 2013
    ..Intramuscular (L-)epinephrine is used as self-medication for serious hypersensitivity reactions. Inhalative administration has the theoretical advantage of a more rapid absorption and better controllability...
  2. doi request reprint Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers
    Oxana Doroshyenko
    ITECRA GmbH and Co KG, Cologne, Germany
    Drug Metab Dispos 41:987-93. 2013
    ..This cocktail study evaluated the interaction potential of the oral lavender oil preparation silexan with major P450 (cytochrome P450) enzymes...
  3. ncbi request reprint Individual variation in factors affecting the steps between dose application and effects of antineoplastic agents
    U Fuhr
    Department of Pharmacology, University of Cologne, Germany
    Int J Clin Pharmacol Ther 43:573-4. 2005
  4. ncbi request reprint Toxicokinetics of acrylamide in humans after ingestion of a defined dose in a test meal to improve risk assessment for acrylamide carcinogenicity
    Uwe Fuhr
    Department of Pharmacology, University Hospital, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany
    Cancer Epidemiol Biomarkers Prev 15:266-71. 2006
    ..This should be considered for quantitative cancer risk assessment...
  5. ncbi request reprint Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach
    U Fuhr
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
    Clin Pharmacol Ther 81:270-83. 2007
    ....
  6. doi request reprint Improvement in the handling of drug-drug interactions
    Uwe Fuhr
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Koln, Germany
    Eur J Clin Pharmacol 64:167-71. 2008
    ..Therefore, the incorporation of DDIs in a more general procedure for personalisation of drug therapy is desirable...
  7. ncbi request reprint The effect of silymarin on oral nifedipine pharmacokinetics
    Uwe Fuhr
    Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
    Planta Med 73:1429-35. 2007
    ..Silymarin thus is not a potent CYP3A4 inhibitor IN VIVO...
  8. doi request reprint Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan
    K Abduljalil
    Department of Pharmacology, Clinical Pharmacology Unit, University Hospital, University of Cologne, Cologne, Germany
    Clin Pharmacol Ther 88:643-51. 2010
    ..Urinary pH was confirmed as a significant covariate for DM renal clearance. These results refine genotype-based predictions of pharmacokinetics for DM and presumably for other CYP2D6 substrates as well...
  9. doi request reprint Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?
    D Tomalik-Scharte
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
    Clin Pharmacol Ther 86:147-53. 2009
    ..Further studies to address the temporal variations in local CYP3A activity are needed to assess its role as a biomarker during CYP3A inhibition...
  10. doi request reprint Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
    J J Vehreschild
    Department I of Internal Medicine, University of Cologne, Cologne, Germany
    Eur J Clin Pharmacol 68:987-95. 2012
    ..To estimate the pharmacokinetic (PK) properties of posaconazole in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing chemotherapy in a clinical setting...
  11. ncbi request reprint Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance
    U Fuhr
    Institute for Pharmacology, Universitat zu Koln, Germany
    Drug Saf 18:251-72. 1998
    ..A place for grapefruit juice as a drug-sparing agent in treatment involving expensive medicine cannot be derived from the information currently available on grapefruit juice interactions...
  12. pmc Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers
    G Zadoyan
    Department of Pharmacology Clinical Pharmacology Unit, University of Cologne, Gleueler Str 24, 50931, Cologne, Germany
    Eur J Clin Pharmacol 68:553-60. 2012
    ..We assessed the human in vivo metabolic drug interaction profile of Ginkgo biloba extract EGb 761® with respect to the activities of major cytochrome P450 (CYP) enzymes...
  13. ncbi request reprint The clinical role of genetic polymorphisms in drug-metabolizing enzymes
    D Tomalik-Scharte
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Koln, Germany
    Pharmacogenomics J 8:4-15. 2008
    ..However, more prospective studies with clinical endpoints are needed before the paradigm of 'personalized medicine' based on DME variants can be established...
  14. ncbi request reprint Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants
    D Rokitta
    Department of Pharmacology, University of Cologne, Gleueler Str 24, 50931 Cologne, Germany
    Curr Drug Metab 11:153-61. 2010
    ..1, CYP2C9.2 and CYP2C9.3), CYP2C8 and/or CYP2C19. Particularly contradictory findings for the same reactions call for some standardization in the assessment of enzyme kinetics...
  15. ncbi request reprint Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers
    D Tomalik-Scharte
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Str 24, 50931 Koln, Germany
    Drug Metab Dispos 33:1859-66. 2005
    ..93-1.00, 0.84-0.96, and 0.97-1.07, respectively). All study drugs were well tolerated. In conclusion, propiverine has a minor potential to cause drug-drug interactions...
  16. doi request reprint Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients
    C Wyen
    Department of Internal Medicine, Hospital of the University of Cologne, Koln, Germany
    Clin Pharmacol Ther 84:75-82. 2008
    ..In conclusion, CYP3A, CYP2D6, and P-glycoprotein are profoundly inhibited in patients receiving ritonavir boosted lopinavir. The covariates investigated are not useful for a priori dose selection...
  17. ncbi request reprint Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration
    S Schroder
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Cologne, Germany
    Int J Clin Pharmacol Ther 42:543-9. 2004
    ..The present study was performed to assess the influence of intestinal site on absorption of the drug as the basis for the development of modified release preparations...
  18. ncbi request reprint Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping
    D Frank
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931, Koln, Germany
    Eur J Clin Pharmacol 63:321-33. 2007
    ..Appropriate metrics need to fulfill pre-defined validation criteria...
  19. ncbi request reprint Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients
    I Tantcheva-Poor
    Institute for Pharmacology, Clinical Pharmacology, 50931 Koln, Germany
    Br J Dermatol 144:1127-32. 2001
    ..Methoxsalen (8-MOP) may cause important pharmacokinetic drug interactions as it has been shown to inhibit and/or induce several drug-metabolizing enzymes in vitro, in animal models and in humans...
  20. ncbi request reprint Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
    Julia Kirchheiner
    Department of Pharmacology, University of Cologne, Gleueler Strasse 24, 50931, Koln, Germany
    Nat Rev Drug Discov 4:639-47. 2005
    ..Here, we argue for the development of concise guidelines for implementation of PGx analyses in drug development and therapy...
  21. doi request reprint Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide
    Dorota Tomalik-Scharte
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Koln, Germany
    Drug Metab Dispos 39:927-32. 2011
    ..In conclusion, CYP2C8*3 does not seem to play an important role in the pharmacokinetics and pharmacodynamics of repaglinide given in a therapeutic dose...
  22. pmc Absorption, pharmacokinetics, and safety of triclosan after dermal administration
    Christian Queckenberg
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Gleueler Str 24, D 50931 Cologne, Germany
    Antimicrob Agents Chemother 54:570-2. 2010
    ..Triclosan can be considered safe for use in hydrophobic creams...
  23. doi request reprint Influence of posture on pharmacokinetics
    Christian Queckenberg
    Department of Pharmacology, Clinical Pharmacology, University Hospital, University of Cologne, Cologne, Germany
    Eur J Clin Pharmacol 65:109-19. 2009
    ..These characteristics may interact with key factors determining the pharmacokinetics of drugs (dissolution, absorption, distribution, metabolism, excretion)...
  24. ncbi request reprint Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer
    M Hunz
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Cologne, Germany
    Clin Pharmacol Ther 81:659-68. 2007
    ..Epirubicin doses were significantly correlated to tumor exposure irrespective of body surface area. There is no specific barrier for epirubicin to reach primary breast cancer tumors...
  25. ncbi request reprint ["Clinically significant" new drug interactions]
    U Fuhr
    Klinische Pharmakologie, Universitat zu Koln
    Med Klin (Munich) 94:120-4. 1999
    ..Several actual examples on interactions with selective serotonin re-uptake inhibitors, HMG-CoA reductase inhibitors, mibefradil, sildenafil, protease inhibitors and with grapefruit juice are discussed...
  26. ncbi request reprint Rate-limiting biotransformation of triamterene is mediated by CYP1A2
    U Fuhr
    Institute for Pharmacology, Clinical Pharmacology, University of Cologne, Germany
    Int J Clin Pharmacol Ther 43:327-34. 2005
    ..To identify the cytochrome P450 enzyme(s) catalyzing hydroxylation of triamterene (the rate-limiting step in the formation of the sulfate ester (STA)), in vitro incubation studies were performed with human liver microsomes...
  27. ncbi request reprint Biotransformation of methylxanthines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Allocation of metabolic pathways to isoforms and inhibitory effects of quinolones
    U Fuhr
    Department of Clinical Pharmacology, University Hospital, Frankfurt am Main, Germany
    Toxicology 82:169-89. 1993
    ..Theophylline was mainly metabolized via 8-hydroxylation. All cell lines tested were able to carry out this reaction, with highest activities in cell lines expressing rat or human P450IA2, or rat P450IA1...
  28. ncbi request reprint Dermal absorption of permethrin following topical administration
    D Tomalik-Scharte
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
    Eur J Clin Pharmacol 61:399-404. 2005
    ..The objective of this study was to determine the systemic exposure of permethrin and the duration of residence in the human body following topical administration...
  29. ncbi request reprint [Clinically significant" new drug interactions]
    U Fuhr
    Klinische Pharmakologie, Universitat zu Koln
    Med Klin (Munich) 95:18-22. 2000
    ..Several actual examples on interactions with selective serotonin re-uptake inhibitors, HMG-CoA reductase inhibitors, mibefradil, sildenafil, protease inhibitors and with grapefruit juice are discussed...
  30. ncbi request reprint Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy
    S Wilde
    Institut fur Pharmakologie, Universitat zu Koln, Klinische Pharmakologie, Germany
    Int J Clin Pharmacol Ther 40:586-8. 2002
  31. pmc Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation
    V Kohl
    Department of Pharmacology, University of Cologne, Cologne, Germany
    Antimicrob Agents Chemother 54:207-12. 2010
    ..Corresponding adjustments of the starting dose according to the presence of diarrhea and according to age appear to be justified before TDM results are available...
  32. doi request reprint In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans
    Oxana Doroshyenko
    Department of Pharmacology, University of Cologne, Cologne, Germany
    Cancer Epidemiol Biomarkers Prev 18:433-43. 2009
    ..No obvious genetic risks or protective factors in xenobiotic-metabolizing enzymes could be determined for exposed subjects...
  33. ncbi request reprint Cytochrome P450 2C9 phenotyping using low-dose tolbutamide
    Alexander Jetter
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany
    Eur J Clin Pharmacol 60:165-71. 2004
    ..However, therapeutically active doses of 500 mg bear the risk of hypoglycaemia, and a tolbutamide-derived parameter based on a single plasma or urine concentration reflecting CYP2C9 activity accurately is lacking...
  34. doi request reprint Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin
    Uwe Fuhr
    Clinical Pharmacology Unit, Department of Pharmacology, Hospital of the University of Cologne, Cologne, Germany
    Eur J Endocrinol 162:1051-8. 2010
    ..Two strengths of a novel ready-to-use liquid preparation of the recombinant human GH (rhGH) Omnitrope were developed to increase the convenience for the patients...
  35. ncbi request reprint Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans
    U Fuhr
    Institute for Pharmacology, Clinical Pharmacology, University of Cologne, Germany
    Clin Pharmacokinet 38:493-504. 2000
    ..The toxicological consequences of enzyme induction in humans are rare, and appear to be mainly limited to hepatoxicity in ethanol-type induction...
  36. doi request reprint Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops
    Khaled Abduljalil
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Gleueler Str 24, D 50931, Koln, Germany
    Eur J Clin Pharmacol 64:521-9. 2008
    ....
  37. ncbi request reprint Assessment of CYP1A2 activity in clinical practice: why, how, and when?
    Mirko S Faber
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Koln, Germany
    Basic Clin Pharmacol Toxicol 97:125-34. 2005
    ..CYP1A2 phenotyping is applied frequently in epidemiologic and drug-drug interaction studies, but its clinical use and usefulness remains to be established...
  38. ncbi request reprint Clinical pharmacokinetics of trospium chloride
    Oxana Doroshyenko
    Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Cologne, Germany
    Clin Pharmacokinet 44:701-20. 2005
    ..The pharmacokinetics of the drug are compatible with twice-daily administration. A once-daily schedule may also be appropriate, but this regimen needs formal clinical evaluation...
  39. ncbi request reprint How may anticancer chemotherapy with fluorouracil be individualised?
    Su arpa Ploylearmsaeng
    Department of Pharmacology, Clinical Pharmacology, University Hospital of Cologne, Cologne, Germany
    Clin Pharmacokinet 45:567-92. 2006
    ....
  40. ncbi request reprint Pharmacogenetics of oral anticoagulants: a basis for dose individualization
    Simone Stehle
    Department of Pharmacology, University of Cologne, Cologne, Germany
    Clin Pharmacokinet 47:565-94. 2008
    ....
  41. ncbi request reprint CYP1A1 alleles in women with focal nodular hyperplasia of the liver (FNH)
    A Lazar
    Department of Pharmacology, University Hospital, University of Cologne, Clinical Pharmacology, Germany
    Int J Clin Pharmacol Ther 42:78-82. 2004
    ..In the study at hand, we aimed to evaluate a possible association between CYP1A1*1, *2A, *2B, and *4 alleles and FNH...
  42. doi request reprint The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro
    Eugen Muschler
    Department of Pharmacology, University of Cologne, Cologne, Germany
    Basic Clin Pharmacol Toxicol 105:374-9. 2009
    ..The evidence for substrate-specific inhibitory effects of pioglitazone on CYP2C-mediated metabolism needs to be tested in further studies...
  43. ncbi request reprint Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2
    Andreas Labedzki
    Institute for Pharmacology, Clinical Pharmacology, University of Koln, Gleueler Strasse 24, 50931 Koln, Germany
    Biochem Pharmacol 63:2159-67. 2002
    ..Our results suggest that an interspecies comparison is required for the metabolism of individual xenobiotics interacting with CYP1A2 prior to the use of mice models to predict its toxicity and/or pharmacological activity in man...
  44. pmc Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration
    Khaled Abduljalil
    Department of Pharmacology, Clinical Pharmacology, University Hospital, University of Cologne, Cologne, Germany
    Antimicrob Agents Chemother 53:2892-901. 2009
    ..6-fold higher level of clarithromycin exposure than the 500-mg b.i.d. dose. This evaluation provides a rationale for safer and more effective therapy with clarithromycin...
  45. ncbi request reprint Time response of cytochrome P450 1A2 activity on cessation of heavy smoking
    Mirko S Faber
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Koln, Germany
    Clin Pharmacol Ther 76:178-84. 2004
    ..Our objective was to determine the time course of CYP1A2 activity changes after smoking cessation in heavy smokers as the basis for dosing adaptation schemes...
  46. doi request reprint Mesalazine pharmacokinetics and NAT2 phenotype
    Hendrik Lück
    Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
    Eur J Clin Pharmacol 65:47-54. 2009
    ..Mesalazine undergoes extensive metabolism by N-acetylation. While there is some evidence for an involvement of N-acetyltransferase (NAT) type 1, a potential role of NAT type 2 (NAT2) in vivo has not been tested...
  47. ncbi request reprint Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity
    Stefan Wilde
    Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
    Clin Pharmacokinet 46:319-33. 2007
    ..The present study was conducted to address the role of pharmacokinetics in individual toxicity...
  48. ncbi request reprint An amperometric biosensor with human CYP3A4 as a novel drug screening tool
    Shiba Joseph
    Institute for Pharmacology, Clinical Pharmacology, University of Koln, Koln, Germany
    Biochem Pharmacol 65:1817-26. 2003
    ..Thus, important requirements for the application of human CYP biosensors in order to identify drugs or drug candidates as substrates or inhibitors to the attached enzyme are fulfilled...
  49. ncbi request reprint Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure
    Alexander Jetter
    Department of Pharmacology, Clinical Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Koln, Germany
    Eur J Clin Pharmacol 60:17-21. 2004
    ..We tested whether these standardization measures were still needed when a more sensitive quantification technique was used...
  50. ncbi request reprint Effects of grapefruit juice and smoking on verapamil concentrations in steady state
    Uwe Fuhr
    Institute for Pharmacology, Clinical Pharmacology, University of Koln, Germany
    Eur J Clin Pharmacol 58:45-53. 2002
    ..Both enzymes contribute to verapamil biotransformation. This study was performed to quantitatively assess the effect of these factors on verapamil pharmacokinetics in steady state...
  51. ncbi request reprint What is the true risk of a pharmacokinetic drug-drug interaction?
    Uwe Fuhr
    Eur J Clin Pharmacol 63:897-9. 2007
  52. ncbi request reprint Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype
    Julia Kirchheiner
    Institute of Pharmacology of Natural Products and Clinical Pharmacology, University of Ulm, Germany
    Clin Pharmacol Ther 80:657-67. 2006
    ..The purpose of this was to clarify the role of this polymorphism with regard to the pharmacokinetics and clinical effects of rosiglitazone...
  53. ncbi request reprint The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers
    Alexander Jetter
    Clin Pharmacol Ther 78:441-3. 2005
  54. ncbi request reprint Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity
    Tobias Klaassen
    Department of Pharmacology, Clinical Pharmacology, Hospital of the University of Cologne, Gleueler Str 24, 50931, Koln, Germany
    Eur J Clin Pharmacol 64:387-98. 2008
    ..We also assessed whether urinary excretion of N-desmethylmephenytoin (nirvanol) might be a useful CYP2B6 metric in in vivo studies...
  55. ncbi request reprint Effects of grapefruit juice on the pharmacokinetics of sildenafil
    Alexander Jetter
    Institute for Pharmacology, Clinical Pharmacology, University of Koln, Germany
    Clin Pharmacol Ther 71:21-9. 2002
    ..In this study we investigated the influence of grapefruit juice, containing inhibitors of intestinal CYP3A4, on the pharmacokinetics of sildenafil and N -desmethylsildenafil...
  56. pmc Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?
    Martina Kinzig-Schippers
    Institute for Biomedical and Pharmaceutical Research, Paul Ehrlich Strasse 19, 90562 Nürnberg Heroldsberg, Germany
    Antimicrob Agents Chemother 49:1733-8. 2005
    ..Prospective clinical trials are required to assess the merits of this approach...
  57. ncbi request reprint Cytochrome P450 enzymes contributing to demethylation of maprotiline in man
    Lars Brachtendorf
    Institute for Pharmacology, Clinical Pharmacology, University of Koln, Germany
    Pharmacol Toxicol 90:144-9. 2002
    ..Based on the parameters obtained, for plasma concentrations of 1 microM 83% (mean) of desmethylmaprotiline formation in vivo is expected to be mediated by CYP2D6 while 17% only may be attributed to CYPIA2 activity...
  58. ncbi request reprint Do data presented at an American Society for Clinical Pharmacology and Therapeutics meeting make it to full publication?
    Markus Riessland
    Clin Pharmacol Ther 75:123-4. 2004